

Sean Emery

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/513293/publications.pdf>

Version: 2024-02-01

257
papers

20,922
citations

18482

62
h-index

10734

138
g-index

258
all docs

258
docs citations

258
times ranked

16893
citing authors

#	ARTICLE	IF	CITATIONS
1	Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. <i>New England Journal of Medicine</i> , 2015, 373, 795-807.	27.0	2,232
2	Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. <i>Lancet, The</i> , 2008, 372, 1881-1893.	13.7	1,560
3	Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection. <i>PLoS Medicine</i> , 2008, 5, e203.	8.4	1,398
4	Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection. <i>Journal of Infectious Diseases</i> , 2011, 203, 780-790.	4.0	957
5	Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection. <i>Journal of Infectious Diseases</i> , 2010, 201, 1788-1795.	4.0	724
6	HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a caseâ€“cohort analysis. <i>Lancet, The</i> , 2008, 372, 1894-1905.	13.7	670
7	Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals. <i>PLoS ONE</i> , 2012, 7, e44454.	2.5	456
8	An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. <i>Lancet, The</i> , 2003, 361, 726-735.	13.7	415
9	Major Clinical Outcomes in Antiretroviral Therapy (ART)â€“Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study. <i>Journal of Infectious Diseases</i> , 2008, 197, 1133-1144.	4.0	364
10	Interleukin-2 Therapy in Patients with HIV Infection. <i>New England Journal of Medicine</i> , 2009, 361, 1548-1559.	27.0	342
11	Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. <i>Lancet HIV,the</i> , 2018, 5, e438-e447.	4.7	337
12	Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. <i>Aids</i> , 2013, 27, 973-979.	2.2	315
13	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. <i>Aids</i> , 2008, 22, F17-F24.	2.2	300
14	Higher Levels of CRP, D-dimer, IL-6, and Hyaluronic Acid Before Initiation of Antiretroviral Therapy (ART) Are Associated With Increased Risk of AIDS or Death. <i>Journal of Infectious Diseases</i> , 2011, 203, 1637-1646.	4.0	287
15	Prevalence of Metabolic Syndrome in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Using International Diabetes Foundation and Adult Treatment Panel III Criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. <i>Diabetes Care</i> , 2007, 30, 113-119.	8.6	267
16	Reversibility of lipodystrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir. <i>Aids</i> , 2004, 18, 1029-1036.	2.2	261
17	No effect of rosiglitazone for treatment of HIV-1 lipodystrophy: randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2004, 363, 429-438.	13.7	241
18	Smoking-Related Health Risks Among Persons With HIV in the Strategies for Management of Antiretroviral Therapy Clinical Trial. <i>American Journal of Public Health</i> , 2010, 100, 1896-1903.	2.7	234

#	ARTICLE	IF	CITATIONS
19	Simplification of Antiretroviral Therapy with Tenofovir+Emtricitabine or Abacavir+Lamivudine: A Randomized, 96-Week Trial. <i>Clinical Infectious Diseases</i> , 2009, 49, 1591-1601.	5.8	203
20	Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study). <i>Journal of Infectious Diseases</i> , 2012, 206, 258-266.	4.0	202
21	Inferior Clinical Outcome of the CD4+ Cell Count-Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels during Follow-up. <i>Journal of Infectious Diseases</i> , 2008, 197, 1145-1155.	4.0	191
22	Continuous antiretroviral therapy decreases bone mineral density. <i>Aids</i> , 2009, 23, 1519-1529.	2.2	188
23	Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation. <i>Journal of the American Heart Association</i> , 2014, 3, e000844.	3.7	184
24	HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. <i>HIV Medicine</i> , 2003, 4, 293-301.	2.2	181
25	Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. <i>Aids</i> , 2007, 21, 2315-2321.	2.2	172
26	Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. <i>Aids</i> , 2007, 21, 2445-2453.	2.2	163
27	In Vivo, Nucleoside Reverse-Transcriptase Inhibitors Alter Expression of Both Mitochondrial and Lipid Metabolism Genes in the Absence of Depletion of Mitochondrial DNA. <i>Journal of Infectious Diseases</i> , 2005, 191, 1686-1696.	4.0	162
28	Predicting risk of cancer during HIV infection. <i>Aids</i> , 2013, 27, 1433-1441.	2.2	158
29	High Levels of Human Antigen-Specific CD4+ T Cells in Peripheral Blood Revealed by Stimulated Coexpression of CD25 and CD134 (OX40). <i>Journal of Immunology</i> , 2009, 183, 2827-2836.	0.8	153
30	Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. <i>Aids</i> , 2010, 24, 697-706.	2.2	150
31	Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naïve adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. <i>Lancet</i> , 2014, 383, 1474-1482.	13.7	144
32	Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 36-43.	2.1	142
33	Activation and Coagulation Biomarkers Are Independent Predictors of the Development of Opportunistic Disease in Patients with HIV Infection. <i>Journal of Infectious Diseases</i> , 2009, 200, 973-983.	4.0	140
34	Studies on lipid peroxidation in normal and tumour tissues. The Yoshida rat liver tumour. <i>Biochemical Journal</i> , 1988, 250, 247-252.	3.7	132
35	Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. <i>PLoS Medicine</i> , 2015, 12, e1001809.	8.4	119
36	Risk for Opportunistic Disease and Death after Reinitiating Continuous Antiretroviral Therapy in Patients with HIV Previously Receiving Episodic Therapy. <i>Annals of Internal Medicine</i> , 2008, 149, 289.	3.9	118

#	ARTICLE	IF	CITATIONS
37	Risk of cancers during interrupted antiretroviral therapy in the SMART study. <i>Aids</i> , 2007, 21, 1957-1963.	2.2	113
38	Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment-naïve, HIV-1 Infected Individuals Commencing cART? A Randomized, Controlled Study. <i>Clinical Infectious Diseases</i> , 2010, 50, 920-929.	5.8	113
39	CD4 Cell Response to 3 Doses of Subcutaneous Interleukin 2: Meta-analysis of 3 Vanguard Studies. <i>Clinical Infectious Diseases</i> , 2004, 39, 115-122.	5.8	109
40	Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin-2 Therapy in Adult Human Immunodeficiency Virus Type 1 Disease. <i>Journal of Infectious Diseases</i> , 2000, 182, 428-434.	4.0	105
41	Pneumonia in HIV-infected Persons. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 630-636.	5.6	104
42	Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 793-802.	9.1	104
43	Lipoprotein particle subclasses, cardiovascular disease and HIV infection. <i>Atherosclerosis</i> , 2009, 207, 524-529.	0.8	100
44	Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. <i>Clinical Trials</i> , 2013, 10, S5-S36.	1.6	100
45	Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. <i>PLoS ONE</i> , 2012, 7, e38377.	2.5	97
46	Outpatient Continuous Intravenous Interleukin-2 or Subcutaneous, Polyethylene Glycol-Modified Interleukin-2 in Human Immunodeficiency Virus-1 Infected Patients: A Randomized, Controlled, Multicenter Study. <i>Journal of Infectious Diseases</i> , 1998, 178, 992-999.	4.0	95
47	Pre-ART Levels of Inflammation and Coagulation Markers Are Strong Predictors of Death in a South African Cohort with Advanced HIV Disease. <i>PLoS ONE</i> , 2012, 7, e24243.	2.5	89
48	Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. <i>HIV Medicine</i> , 2006, 7, 105-111.	2.2	88
49	An Objective Lipodystrophy Severity Grading Scale Derived From the Lipodystrophy Case Definition Score. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 571-576.	2.1	82
50	The Evaluation of Subcutaneous Proleukin® (interleukin-2) in a Randomized International Trial. <i>Contemporary Clinical Trials</i> , 2002, 23, 198-220.	1.9	81
51	Phase coexistence near a morphotropic phase boundary in Sm-doped BiFeO3 films. <i>Applied Physics Letters</i> , 2010, 97, .	3.3	77
52	A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. <i>Aids</i> , 2000, 14, 1171-1180.	2.2	76
53	HIV DNA Subspecies Persist in both Activated and Resting Memory CD4 ⁺ T Cells during Antiretroviral Therapy. <i>Journal of Virology</i> , 2014, 88, 3516-3526.	3.4	76
54	An Ad5-Vectored HIV-1 Vaccine Elicits Cell-mediated Immunity but does not Affect Disease Progression in HIV-1 infected Male Subjects: Results From a Randomized Placebo-Controlled Trial (The Step Study). <i>Journal of Infectious Diseases</i> , 2011, 203, 765-772.	4.0	72

#	ARTICLE	IF	CITATIONS
55	Factors Associated With Adherence Amongst 5295 People Receiving Antiretroviral Therapy as Part of an International Trial. <i>Journal of Infectious Diseases</i> , 2013, 208, 40-49.	4.0	72
56	Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 406-416.	4.7	72
57	Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection. <i>Aids</i> , 2017, 31, 953-963.	2.2	72
58	Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. <i>Aids</i> , 2011, 25, 2069-2078.	2.2	69
59	Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. <i>Lancet HIV</i> , 2015, 2, e42-e51.	4.7	68
60	A Randomized, Controlled, Phase II Trial Comparing Escalating Doses of Subcutaneous Interleukin-2 plus Antiretrovirals versus Antiretrovirals Alone in Human Immunodeficiency Virus-Infected Patients with CD4+Cell Counts $\geq 350/\text{mm}^3$. <i>Journal of Infectious Diseases</i> , 2000, 181, 1614-1621.	4.0	67
61	Adjudicated Morbidity and Mortality Outcomes by Age among Individuals with HIV Infection on Suppressive Antiretroviral Therapy. <i>PLoS ONE</i> , 2014, 9, e95061.	2.5	67
62	Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. <i>Aids</i> , 2010, 24, 1877-1886.	2.2	66
63	Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx262.	0.9	65
64	Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. <i>Aids</i> , 2008, 22, 2279-2289.	2.2	64
65	Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. <i>Aids</i> , 2011, 25, 367-377.	2.2	62
66	Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. <i>Aids</i> , 2012, 26, 543-550.	2.2	62
67	The search for an HIV cure: tackling latent infection. <i>Lancet Infectious Diseases</i> , 2013, 13, 614-621.	9.1	61
68	Plasma HIV Viral Rebound following Protocol-Indicated Cessation of ART Commenced in Primary and Chronic HIV Infection. <i>PLoS ONE</i> , 2012, 7, e43754.	2.5	60
69	Factors Associated with D-Dimer Levels in HIV-Infected Individuals. <i>PLoS ONE</i> , 2014, 9, e90978.	2.5	60
70	Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 380-387.	3.0	59
71	Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. <i>Aids</i> , 2010, 24, 857-865.	2.2	59
72	HIV Replication Alters the Composition of Extrinsic Pathway Coagulation Factors and Increases Thrombin Generation. <i>Journal of the American Heart Association</i> , 2013, 2, e000264.	3.7	59

#	ARTICLE	IF	CITATIONS
73	HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV. <i>Journal of Virology</i> , 2017, 91, .	3.4	59
74	A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. <i>Aids</i> , 2006, 20, 294-297.	2.2	58
75	Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatmentâ€œNaive, HIVâ€œInfected Subjects: Week 48 Data from the Altair Study. <i>Clinical Infectious Diseases</i> , 2010, 51, 855-864.	5.8	57
76	Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. <i>Clinical Infectious Diseases</i> , 2013, 57, 112-121.	5.8	56
77	A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. <i>Artificial Intelligence in Medicine</i> , 2009, 47, 63-74.	6.5	55
78	Intensification of Antiretroviral Therapy With Raltegravir or Addition of Hyperimmune Bovine Colostrum in HIV-Infected Patients With Suboptimal CD4+ T-Cell Response: A Randomized Controlled Trial. <i>Journal of Infectious Diseases</i> , 2011, 204, 1532-1540.	4.0	54
79	The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies. <i>PLoS ONE</i> , 2013, 8, e57121.	2.5	54
80	Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. <i>Clinical Infectious Diseases</i> , 2008, 47, 1468-1475.	5.8	53
81	Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600Âµmg in Treatment-Naïve HIV-Infected Patients at 96ÂµWeeks: Results of the ENCORE1 Study. <i>Clinical Pharmacokinetics</i> , 2016, 55, 861-873.	3.5	51
82	Buffalo Hump Seen in HIV-Associated Lipodystrophy is Associated With Hyperinsulinemia But Not Dyslipidemia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 156-162.	2.1	50
83	Improvements in antiretroviral therapy outcomes over calendar time. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 194-199.	3.8	50
84	Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIVâ€œPositive Participants in the START (Strategic Timing of Antiretroviral) Tj ETQq0 0 0 rgt /Overlock 10 Tf 5	3.7	49
85	Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. <i>Aids</i> , 2010, 24, 2657-2663.	2.2	49
86	CD8+ Lymphocyte Responses to Antiretroviral Therapy of HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 13, 320-326.	0.3	49
87	Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN γ or IL-12. <i>Vaccine</i> , 2004, 23, 188-197.	3.8	47
88	Interruption of antiretroviral therapy is associated with increased plasma cystatin C. <i>Aids</i> , 2009, 23, 71-82.	2.2	47
89	Studies on the hyperplasia (â€œregenerationâ€œ™) of the rat liver following partial hepatectomy. Changes in lipid peroxidation and general biochemical aspects. <i>Biochemical Journal</i> , 1990, 265, 51-59.	3.7	46
90	Lipodystrophy following antiretroviral therapy of primary HIV infection. <i>Aids</i> , 2000, 14, 2406-2407.	2.2	46

#	ARTICLE	IF	CITATIONS
91	Randomized, open-Label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study. <i>HIV Clinical Trials</i> , 2002, 3, 177-185.	2.0	45
92	Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. <i>Aids</i> , 2011, 25, 2133-2142.	2.2	45
93	Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. <i>PLoS ONE</i> , 2015, 10, e0139981.	2.5	45
94	The Quality of Informed Consent in a Clinical Research Study in Thailand. <i>IRB: Ethics & Human Research</i> , 2005, 27, 9.	0.8	44
95	Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. <i>Aids</i> , 2011, 25, 1727-1735.	2.2	44
96	Development of Diagnostic Criteria for Serious Non-AIDS Events in HIV Clinical Trials. <i>HIV Clinical Trials</i> , 2010, 11, 205-219.	2.0	41
97	Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trial. <i>Aids</i> , 2011, 25, 1207-1217.	2.2	40
98	Immune reconstitution in HIV infection. <i>Current Opinion in Immunology</i> , 1997, 9, 568-572.	5.5	39
99	Biomarkers of Inflammation and Coagulation Are Associated With Mortality and Hepatitis Flares in Persons Coinfected With HIV and Hepatitis Viruses. <i>Journal of Infectious Diseases</i> , 2013, 207, 1379-1388.	4.0	39
100	The Opposites Attract Study of viral load, HIV treatment and HIV transmission in serodiscordant homosexual male couples: design and methods. <i>BMC Public Health</i> , 2014, 14, 917.	2.9	39
101	A Randomized, Multicenter, Open-Label Study of Poly-L-Lactic Acid for HIV-1 Facial Lipoatrophy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 46, 581-589.	2.1	38
102	Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. <i>Aids</i> , 2013, 27, 2403-2411.	2.2	38
103	Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 980-989.	10.7	38
104	Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a "high-affinity" FcγR1a genotype. <i>Aids</i> , 2010, 24, 1983-1990.	2.2	37
105	Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1878-1888.	3.0	37
106	Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels. <i>Aids</i> , 2015, 29, 911-919.	2.2	37
107	Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals. <i>Scientific Reports</i> , 2017, 7, 10934.	3.3	36
108	Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. <i>HIV Medicine</i> , 2012, 13, 245-251.	2.2	35

#	ARTICLE	IF	CITATIONS
109	Safety and Immunogenicity of UBI HIV-1MNOctameric V3 Peptide Vaccine Administered by Subcutaneous Injection. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 29-32.	1.1	33
110	A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand. <i>Aids</i> , 2000, 14, 2509-2513.	2.2	33
111	Effect of Rosiglitazone on Peroxisome Proliferator-Activated Receptor β Gene Expression in Human Adipose Tissue Is Limited by Antiretroviral Drug-Induced Mitochondrial Dysfunction. <i>Journal of Infectious Diseases</i> , 2008, 198, 1794-1803.	4.0	33
112	Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 480-490.	3.8	33
113	Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1427-1433.	3.2	32
114	Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens. <i>Clinical and Experimental Immunology</i> , 1998, 113, 85-91.	2.6	31
115	Outcomes of Influenza A(H1N1)pdm09 Virus Infection: Results from Two International Cohort Studies. <i>PLoS ONE</i> , 2014, 9, e101785.	2.5	31
116	Therapeutic Strategies for HIV Infection – Time to Think Hard. <i>New England Journal of Medicine</i> , 1998, 339, 1319-1321.	27.0	30
117	A Randomized Factorial Trial Comparing 4 Treatment Regimens in Treatment-Naive HIV-Infected Persons with AIDS and/or a CD4 Cell Count <200 Cells/ μ L in South Africa. <i>Journal of Infectious Diseases</i> , 2010, 202, 1529-1537.	4.0	30
118	Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization. <i>Clinical Trials</i> , 2017, 14, 264-276.	1.6	30
119	Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. <i>Aids</i> , 2003, 17, 1889-1896.	2.2	29
120	Randomised, Placebo-Controlled, Phase I/IIa Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon- γ in HIV-1 Infected Subjects. <i>Hum Vaccin</i> , 2005, 1, 232-238.	2.4	29
121	HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. <i>Aids</i> , 2005, 19, 169-178.	2.2	29
122	N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. <i>Aids</i> , 2011, 25, 651-657.	2.2	29
123	Combined Analysis of Two-Year Follow-Up from Two Open-Label Randomized Trials Comparing Efficacy of Three Nucleoside Reverse Transcriptase Inhibitor Backbones for Previously Untreated HIV-1 Infection: OzCombo 1 and 2. <i>HIV Clinical Trials</i> , 2003, 4, 252-261.	2.0	28
124	The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. <i>Aids</i> , 2005, 19, 1393-1399.	2.2	28
125	Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 48, 26-34.	2.1	28
126	Effects of α -Tocopherol on Carbon Tetrachloride Metabolism in Rat Liver Microsomes. <i>Free Radical Research Communications</i> , 1987, 3, 325-330.	1.8	27

#	ARTICLE	IF	CITATIONS
127	Episodic Antiretroviral Therapy Increases HIV Transmission Risk Compared With Continuous Therapy: Results of a Randomized Controlled Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 49, 142-150.	2.1	27
128	Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, 1026-1032.	5.8	27
129	A Randomised Trial Comparing Genotypic and Virtual Phenotypic Interpretation of HIV Drug Resistance: The CREST Study. <i>PLOS Clinical Trials</i> , 2006, 1, e18.	3.5	26
130	Cancer: the effects of HIV and antiretroviral therapy, and implications for early antiretroviral therapy initiation. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 183-187.	3.8	26
131	Role of Interleukin-2 in Patients with HIV Infection. <i>Drugs</i> , 2010, 70, 1115-1130.	10.9	26
132	Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 635-640.	3.0	26
133	Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals. <i>HIV Medicine</i> , 2014, 15, 116-123.	2.2	26
134	Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. <i>HIV Medicine</i> , 2015, 16, 1-9.	2.2	26
135	The impact of registration of clinical trials units: The UK experience. <i>Clinical Trials</i> , 2015, 12, 166-173.	1.6	26
136	Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial. <i>Lancet HIV</i> , 2016, 3, e343-e350.	4.7	26
137	The development of artificial neural networks to predict virological response to combination HIV therapy. <i>Antiviral Therapy</i> , 2007, 12, 15-24.	1.0	26
138	Influence of IFN β Co-Expression on the Safety and Antiviral Efficacy of Recombinant Fowlpox Virus HIV Therapeutic Vaccines Following Interruption of Antiretroviral Therapy. <i>Hum Vaccin</i> , 2007, 3, 260-267.	2.4	25
139	Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. <i>Aids</i> , 2014, 28, 1791-1796.	2.2	25
140	Visceral and Subcutaneous Adiposity Measurements in Adults: Influence of Measurement Site. <i>Obesity</i> , 2007, 15, 1441-1447.	3.0	24
141	Detection of a Substantial Rate of Multidrug-Resistant Tuberculosis in an HIV-Infected Population in South Africa by Active Monitoring of Sputum Samples. <i>Clinical Infectious Diseases</i> , 2010, 50, 1053-1059.	5.8	24
142	The effect of cimetidine and ranitidine on paracetamol glucuronidation and sulphation in cultured rat hepatocytes. <i>Biochemical Pharmacology</i> , 1985, 34, 1415-1421.	4.4	23
143	Immunomodulators as adjunctive therapy for HIV-1 infection. <i>Journal of Clinical Virology</i> , 2001, 22, 289-295.	3.1	23
144	An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. <i>Hum Vaccin</i> , 2010, 6, 835-840.	2.4	23

#	ARTICLE	IF	CITATIONS
145	The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool. <i>Aids</i> , 2011, 25, 1855-1863.	2.2	23
146	Quality Assessment Program for Genotypic Antiretroviral Testing Improves Detection of Drug Resistance Mutations. <i>Journal of Clinical Microbiology</i> , 2003, 41, 227-236.	3.9	22
147	Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited setting. <i>International Journal of STD and AIDS</i> , 2008, 19, 529-532.	1.1	22
148	Influence of Rosiglitazone on Flow-Mediated Dilation and Other Markers of Cardiovascular Risk in HIV-Infected Patients with Lipotrophy. <i>Antiviral Therapy</i> , 2005, 10, 135-143.	1.0	22
149	Evaluation of ultrasound for assessing facial lipotrophy in a randomized, placebo-controlled trial. <i>Aids</i> , 2005, 19, 1325-1327.	2.2	21
150	HIV Replication, Inflammation, and the Effect of Starting Antiretroviral Therapy on Plasma Asymmetric Dimethylarginine, a Novel Marker of Endothelial Dysfunction. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 128-134.	2.1	21
151	Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection. <i>PLoS ONE</i> , 2015, 10, e0118228.	2.5	21
152	Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 122-132.	5.8	21
153	Post-trial Access to Tested Interventions: The Views of IRB/REC Chair, Investigators, and Research Participants in a Multinational HIV/AIDS Study. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 837-841.	1.1	20
154	Changes in plasma lipidome following initiation of antiretroviral therapy. <i>PLoS ONE</i> , 2018, 13, e0202944.	2.5	20
155	Regulatory approvals in a large multinational clinical trial. <i>Contemporary Clinical Trials</i> , 2002, 23, 59-66.	1.9	19
156	Therapeutic vaccination against HIV: current progress and future possibilities. <i>Clinical Science</i> , 2006, 110, 59-71.	4.3	19
157	A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK "Vanguard Study. <i>PLOS Clinical Trials</i> , 2006, 1, e3.	3.5	19
158	Substantial Improvements in Performance Indicators Achieved in a Peripheral Blood Mononuclear Cell Cryopreservation Quality Assurance Program Using Single Donor Samples. <i>Vaccine Journal</i> , 2007, 14, 52-59.	3.1	19
159	A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 143-149.	2.1	19
160	Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2018, 5, e553-e559.	4.7	19
161	Reporting and Evaluation of HIV-Related Clinical Endpoints in Two Multicenter International Clinical Trials. <i>HIV Clinical Trials</i> , 2006, 7, 125-141.	2.0	18
162	Antiretroviral roll-out: the problem of second-line therapy. <i>Lancet</i> , 2009, 374, 185-186.	13.7	18

#	ARTICLE	IF	CITATIONS
163	Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study. PLoS ONE, 2013, 8, e56249.	2.5	18
164	The Safety, Efficacy, and Pharmacokinetic Profile of a Switch in Antiretroviral Therapy to Saquinavir, Ritonavir, and Atazanavir Alone for 48 Weeks and a Switch in the Saquinavir Formulation. Clinical Infectious Diseases, 2007, 44, 1475-1483.	5.8	17
165	Effects of Intermittent IL-2 Alone or with Peri-Cycle Antiretroviral Therapy in Early HIV Infection: The STALWART Study. PLoS ONE, 2010, 5, e9334.	2.5	17
166	Immune-based therapies in HIV infection. Aids, 1996, 10, S159-164.	2.2	16
167	Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. Aids, 2009, 23, 2222-2223.	2.2	16
168	Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study. Antiviral Therapy, 2011, 16, 667-675.	1.0	16
169	Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015. Open Forum Infectious Diseases, 2017, 4, ofx212.	0.9	16
170	Raltegravir: a new choice in HIV and new chances for research. Lancet, The, 2009, 374, 764-766.	13.7	15
171	Immunotherapies in HIV-1 infection. Current Opinion in HIV and AIDS, 2009, 4, 188-193.	3.8	15
172	Bone Mineral Density Over 96 Weeks in Adults Failing First-Line Therapy Randomized to Raltegravir/Lopinavir/Ritonavir Compared With Standard Second-Line Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 161-168.	2.1	15
173	Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) Trial. Open Forum Infectious Diseases, 2016, 3, ofw213.	0.9	15
174	Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial. Hepatology, 2019, 69, 1135-1150.	7.3	15
175	Health-Related Quality of Life Outcomes in HIV-Infected Patients Starting Different Combination Regimens in a Randomized Multinational Trial: The INITIO-QoL Substudy. AIDS Research and Human Retroviruses, 2007, 23, 1215-1222.	1.1	14
176	A Novel Chemokine-Receptor-5 (CCR5) Blocker, SCH532706, Has Differential Effects on CCR5+CD4+and CCR5+CD8+T Cell Numbers in Chronic HIV Infection. AIDS Research and Human Retroviruses, 2010, 26, 653-661.	1.1	14
177	Changes in Lipids and Lipoprotein Particle Concentrations After Interruption of Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 275-284.	2.1	14
178	Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: The INSIGHT FLU 002 and FLU 003 studies. Vaccine, 2011, 29, B56-B62.	3.8	14
179	Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption. Journal of Virology, 2017, 91, .	3.4	14
180	HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2-3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy. PLoS ONE, 2013, 8, e77138.	2.5	14

#	ARTICLE	IF	CITATIONS
181	Dose-Response Relationship of DNA and Recombinant Fowlpox Virus Prime-Boost HIV Vaccines: Implications for Future Trials. <i>Hum Vaccin</i> , 2006, 2, 134-136.	2.4	13
182	Benefits and Burdens of Participation in a Longitudinal Clinical Trial. <i>Journal of Empirical Research on Human Research Ethics</i> , 2009, 4, 89-97.	1.3	13
183	The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. <i>Aids</i> , 2010, 24, 353-563.	2.2	13
184	Genotypic Resistance at Viral Rebound Among Patients Who Received Lopinavir/Ritonavir-Based or Efavirenz-Based First Antiretroviral Therapy in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 304-308.	2.1	13
185	An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1104-1110.	3.0	13
186	Assessing site performance in the Altair study, a multinational clinical trial. <i>Trials</i> , 2015, 16, 138.	1.6	13
187	Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 841-850.	1.1	13
188	The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis. <i>Journal of Infectious Diseases</i> , 2019, 219, 254-263.	4.0	13
189	Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm ³ : Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 10-17.	2.1	13
190	Closeout of Four Phase II Vanguard Trials and Patient Rollover into a Large International Phase III HIV Clinical Endpoint Trial. <i>Contemporary Clinical Trials</i> , 2001, 22, 42-48.	1.9	12
191	Limited Evolution of HIV Antiretroviral Drug Resistance-Associated Mutations During the Performance of Drug Resistance Testing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 32, 57-61.	2.1	12
192	Haemoglobin and Anaemia in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 329-337.	1.0	12
193	Short Communication: CD4 T Cell Declines Occurring During Suppressive Antiretroviral Therapy Reflect Continued Production of Casp8p41. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 476-479.	1.1	12
194	Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV. <i>Osteoporosis International</i> , 2016, 27, 1737-1745.	3.1	12
195	Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 345-353.	2.1	12
196	Three-Year Durability of Dual-Nucleoside Versus Triple-Nucleoside Therapy in a Thai Population With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 693-701.	2.1	11
197	Poly-l-lactic acid for HIV-related facial lipoatrophy: 48-week follow-up. <i>HIV Medicine</i> , 2009, 10, 163-172.	2.2	11
198	Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy. <i>Neuroradiology</i> , 2012, 54, 1331-1339.	2.2	11

#	ARTICLE	IF	CITATIONS
199	Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect. <i>Journal of NeuroVirology</i> , 2013, 19, 383-392.	2.1	11
200	Differences in the Direction of Change of Cerebral Function Parameters Are Evident over Three Years in HIV-Infected Individuals Electively Commencing Initial cART. <i>PLoS ONE</i> , 2015, 10, e0118608.	2.5	11
201	HIV dynamics linked to memory CD4+ T cell homeostasis. <i>PLoS ONE</i> , 2017, 12, e0186101.	2.5	11
202	Evolution of CD4+ T Cell Count in HIV-1-Infected Adults Receiving Antiretroviral Therapy with Sustained Long-Term Virological Suppression. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 569-576.	1.1	10
203	Enfuvirtide in HIV-1-Infected Individuals Changing Therapy to A Nucleoside Reverse Transcriptase Inhibitor Sparing Regimen: The Alliance Study. <i>Antiviral Therapy</i> , 2006, 11, 409-419.	1.0	10
204	Informed Consent: Practices and Views of Investigators in a Multinational Clinical Trial. <i>IRB: Ethics & Human Research</i> , 2005, 27, 13.	0.8	9
205	Dietary Intake in HIV-Infected Men with Lipodystrophy: Relationships with Body Composition, Visceral Fat, Lipid, Glucose and Adipokine Metabolism. <i>Current HIV Research</i> , 2009, 7, 456-461.	0.5	9
206	Empirical evaluation of the need for "on-going consent"™ in clinical research. <i>Aids</i> , 2011, 25, 107-114.	2.2	9
207	Biomarkers and Electrocardiographic Evidence of Myocardial Ischemia in Patients With Human Immunodeficiency Virus Infection. <i>American Journal of Cardiology</i> , 2013, 111, 760-764.	1.6	9
208	A Phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients. <i>Antiviral Therapy</i> , 2009, 14, 111-115.	1.0	9
209	Latent reservoirs of HIV infection: Flushing with IL-2?. <i>Nature Medicine</i> , 1999, 5, 611-612.	30.7	8
210	A Phase I Study of the Pharmacokinetics and Safety of Passive Immunotherapy with Caprine Anti-HIV Antibodies, PEHRG214, in HIV-1-Infected Individuals. <i>HIV Clinical Trials</i> , 2004, 5, 91-98.	2.0	8
211	The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. <i>Clinical Trials</i> , 2006, 3, 119-132.	1.6	8
212	Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT). <i>HIV Medicine</i> , 2011, 12, 219-227.	2.2	8
213	Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals. <i>Aids</i> , 2012, 26, 1707-1717.	2.2	8
214	Results of External Quality Assessment for Proviral DNA Testing of HIV Tropism in the Maraviroc Switch Collaborative Study. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2063-2071.	3.9	8
215	Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. <i>HIV Medicine</i> , 2015, 16, 30-36.	2.2	8
216	In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 708-717.	2.3	8

#	ARTICLE	IF	CITATIONS
217	ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 456-462.	2.1	8
218	Selective exclusion of treatment arms in multi-arm randomized clinical trials. <i>Statistics in Medicine</i> , 2003, 22, 19-30.	1.6	7
219	Evaluation of Subcutaneous Proleukin (Interleukin-2) in a Randomized International Trial (ESPRIT): Geographical and Gender Differences in the Baseline Characteristics of Participants. <i>HIV Clinical Trials</i> , 2006, 7, 70-85.	2.0	7
220	Metabolic disorders and cardiovascular consequences of HIV infection and antiretroviral therapy. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 381-390.	3.1	7
221	Short Communication: HIV Blips While on Antiretroviral Therapy Can Indicate Consistently Detectable Viral Levels Due to Assay Underreporting. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1621-1625.	1.1	7
222	An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2928-2937.	3.0	7
223	Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial—The ENCORE1 Study. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 654-658.	2.0	7
224	Electrocardiographic Spatial QRS-T Angle and Incident Cardiovascular Disease in HIV-Infected Patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] Study). <i>American Journal of Cardiology</i> , 2013, 111, 118-124.	1.6	6
225	Pre-therapy inflammation and coagulation activation and long-term CD4 count responses to the initiation of antiretroviral therapy. <i>HIV Medicine</i> , 2015, 16, 449-454.	2.2	6
226	Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. <i>Lancet HIV</i> , 2017, 4, e13-e20.	4.7	6
227	Disease Progression and Fatal Outcomes in HIV-Infected Patients during Interruption of Antiretroviral Treatment. <i>Journal of Infectious Diseases</i> , 2008, 197, 775-775.	4.0	5
228	Predicting the potential benefits of early initiation of ART: time to do a trial to find out. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 165-166.	3.8	5
229	Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial). <i>HIV Medicine</i> , 2011, 12, 602-609.	2.2	5
230	The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV. <i>Aids</i> , 2012, 26, 2337-2344.	2.2	5
231	Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine. <i>PLoS ONE</i> , 2011, 6, e26885.	2.5	5
232	HLA Alleles Association with Changes in Bone Mineral Density in HIV-1-Infected Adults Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. <i>PLoS ONE</i> , 2014, 9, e93333.	2.5	5
233	Chemokine receptor genotype and response to interleukin-2 therapy in HIV-1-infected individuals. <i>Clinical Immunology</i> , 2003, 106, 36-40.	3.2	4
234	Hip Structural Parameters over 96 Weeks in HIV-Infected Adults Switching Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. <i>PLoS ONE</i> , 2014, 9, e94858.	2.5	4

#	ARTICLE	IF	CITATIONS
235	Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study. <i>HIV Medicine</i> , 2018, 19, 65-71.	2.2	4
236	Computational models as predictors of HIV treatment outcomes for the Phidisa cohort in South Africa. <i>Southern African Journal of HIV Medicine</i> , 2016, 17, 450.	0.9	4
237	Effect of nucleoside reverse transcriptase inhibitors on CD4 Tâ€cell recovery in HIVâ€1â€infected individuals receiving longâ€term fully suppressive combination antiretroviral therapy. <i>HIV Medicine</i> , 2009, 10, 143-151.	2.2	3
238	Protease inhibitors and cardiac autonomic function in HIV-infected patients: a cross-sectional analysis from the Strategies for Management of Antiretroviral Therapy (SMART) Trial. <i>BMJ Open</i> , 2013, 3, e002523.	1.9	3
239	Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: Results from the Strategies for Management of Antiretroviral Therapy [SMART] Study. <i>Journal of Electrocardiology</i> , 2014, 47, 264-271.	0.9	3
240	Influence of <i>CYP3A5</i> and <i>SLCO1B1</i> polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients. <i>Pharmacogenomics</i> , 2019, 20, 517-527.	1.3	3
241	Drug companies have a duty to continue treatment. <i>BMJ: British Medical Journal</i> , 1997, 314, 889-889.	2.3	3
242	HIV medicine. <i>Medical Journal of Australia</i> , 2002, 176, 21-21.	1.7	2
243	Project Phidisa: development of clinical research capacity within the South African National Defence Force. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 69-76.	3.8	2
244	Predictors of Clinical Progression in HIV-1-Infected Adults Initiating Combination Antiretroviral Therapy with Advanced Disease in the Asia-Pacific Region. <i>Journal of the International Association of Providers of AIDS Care</i> , 2013, 12, 270-277.	1.5	2
245	A comparison of computational models with and without genotyping for prediction of response to secondâ€line <sc>HIV</sc> therapy. <i>HIV Medicine</i> , 2014, 15, 442-448.	2.2	2
246	Impact of early antiretroviral treatment on sexual behaviour. <i>Aids</i> , 2019, 33, 2337-2350.	2.2	2
247	The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa. <i>PLoS ONE</i> , 2013, 8, e54435.	2.5	2
248	Antiretro viral therapy of human immunodeficiency virus typeâ€1 (HIVâ€1) infection. <i>Australian and New Zealand Journal of Medicine</i> , 1995, 25, 344-349.	0.5	1
249	Clinical trials of antiretroviral therapy in developing countries. <i>Australian and New Zealand Journal of Medicine</i> , 2000, 30, 3-4.	0.5	1
250	P15-01. Willingness to participate in actual preventive HIV vaccine phase I/IIa trial in Bangkok, Thailand. <i>Retrovirology</i> , 2009, 6, .	2.0	1
251	Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial. <i>Antiviral Therapy</i> , 2017, 23, 21-32.	1.0	1
252	Reply. <i>Journal of Infectious Diseases</i> , 2001, 183, 680-680.	4.0	0

#	ARTICLE	IF	CITATIONS
253	Short Communication: Nonnucleoside Reverse Transcriptase Inhibitor Fold Change or Plasma Concentration as a Predictor of Virological Response over 48 Weeks in Highly Treatment Experienced HIV-Positive Individuals. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 338-341.	1.1	0
254	Antiretroviral agents: Focus on Maraviroc for the Treatment of HIV-1-Infected Adults. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S5420.	0.4	0
255	Prospective evidence that HIV lipotrophy and visceral adiposity are partially independent processes. <i>Open Access Journal of Clinical Trials</i> , 0, , 1.	1.5	0
256	Reply to "Issues on Results of the External Quality Assessment for Proviral DNA Testing of HIV-1 Tropism in the Maraviroc Switch Collaborative Study". <i>Journal of Clinical Microbiology</i> , 2013, 51, 4287-4287.	3.9	0
257	Comparison of central and local HIV-1 RNA quantification from two international clinical trials. <i>Aids</i> , 2014, 28, 2480-2483.	2.2	0